BridgeBio Oncology Therapeutics, Inc. (BBOT) — Cash Flow-to-Debt Ratio
BridgeBio Oncology Therapeutics, Inc. (BBOT) has a Cash Flow-to-Debt Ratio of -0.79x as of March 2026, meaning its operating cash flow of $-35.92 Million could theoretically repay -1% of its total liabilities ($45.37 Million) in one year. Explore investment intensity of BridgeBio Oncology Therapeutics, Inc. to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
BridgeBio Oncology Therapeutics, Inc. Cash Flow-to-Debt Ratio (2023–2025)
Historical debt coverage capacity for BridgeBio Oncology Therapeutics, Inc. across 3 annual periods. Also explore BridgeBio Oncology Therapeutics, Inc. asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for BridgeBio Oncology Therapeutics, Inc. (2023–2025)
Year-by-year debt coverage analysis for BridgeBio Oncology Therapeutics, Inc.. For market capitalisation and broader financial context, see BBOT company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.05x | $-113.89 Million | $37.28 Million | ▼ -2182.6% |
| 2024 | -0.13x | $-763.82K | $5.71 Million | ▲ +99.9% |
| 2023 | -131.36x | $-52.08 Million | $396.46K | — |